CAS: 1025708-31-9; 2-Cyanopyrimidine-5-Boronic Acid Pinacol Ester

该化合物是一种多用途碳酸酯衍生物,广泛用于铃木-米亚乌拉的交叉组合反应.其糖浆核心,与一个环状体组一起发挥作用,在形成碳碳-碳联结方面,特别是在制药和农用化学合成方面,增强了反应性和选择性. 酸酯组改善了稳定性和处理能力,降低了水解敏感度,与免费的碳酸相比.该化合物因其与多种反应条件的兼容性,对于构建复杂的热循环框架很有价值. 高纯度和连续性能使它成为研究和工业应用的可靠中间体. 建议在惰性条件下妥善储存,以保持其完整性.

结构式图片

相似化合物

1164100-81-5 1052686-67-5 1631981-66-2

欧盟法规

C&L通报

上下游产品

2-cyanopyrimidine bis(pinacol)diborane 5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyrimidine-2-carbonitrile

合成工艺路线路线简述

  • 合成目标产物 2-Cyanopyrimidine-5-Boronic Acid Pinacol Ester 主要起始原料 2-Cyanopyrimidine And Bis(Pinacolato)Diboron
  • (文献来源)合成步骤主要原料 2-Cyanopyrimidine 和 Bis(Pinacolato)Diboron
📜2-氰基嘧啶,联硼酸频那醇酯置于(1,5-Cyclooctadiene)(Methoxy)Iridium(I) Dimer,3,4,7,8-四甲基-1,10-菲罗啉体系中,用 四氢呋喃 用作溶剂,化学反应 24.0H,反应生成2-氰基嘧啶-5-硼酸频那酯
参考文献:从ag到pd的两种配体转移:在途中(sipr)pd(cf2H)(x)的转移及其在一锅ch硼化/二氟甲基化中的应用.
标题:从ag到pd的两种配体转移:在途中(sipr)pd(cf2H)(x)的转移及其在一锅ch硼化/二氟甲基化中的应用.
摘要:Nhc配体和二氟甲基基团从[(sipr)ag(cf2H)]同时转移到pdx2(x = Cl,Oac和opiv)的过程,用于制备[(sipr)pd(cf2H)x描述复合物.这些络合物是空气稳定的,易于通过芳基频哪醇硼酸酯/还原消除进行重金属化,从而以高收率生成arcf2H.基于这一发现,开发了用于制备二氟甲基化(杂)芳烃的第一个单锅ch硼化和二氟甲基化方法.
Doi:10.1021/acs.Joc.9B03296

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知